1921
Volume 76, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Few therapeutic options are available for mucocutaneous leishmaniasis (MCL). We conducted a randomized open trial to evaluate the efficacy, safety, and tolerance of parenteral aminosidine sulphate (AS) 14 mg/kg/d for 21 days compared with intravenous meglumine antimonate (MA) 20 mg/kg/d for 28 days in patients with moderate MCL in Cuzco, Peru. Cure was defined as complete healing with re-epithelialization within 1 year of follow-up. The trial was stopped after 38 patients were enrolled (17 in the MA group and 21 in the AS group) because of marked differences in response. Study groups were comparable in baseline characteristics. Cure rates were 0/21 in the AS group compared with 8/17 (47%, 95% confidence interval: 23–71%) in the MA group ( < 0.001). Side effects and laboratory abnormalities were mild in both groups. We conclude that parenteral AS given on its own is not effective for MCL in Peru.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2007.76.1128
2007-06-01
2019-11-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/76/6/0761128.html?itemId=/content/journals/10.4269/ajtmh.2007.76.1128&mimeType=html&fmt=ahah

References

  1. Marsden PD, 1986. Mucosal leishmaniasis (“espundia” Escomel, 1911). Trans R Soc Trop Med Hyg 80 : 859–876. [Google Scholar]
  2. Lucas CM, Franke ED, Cachay MI, Tejada A, Cruz ME, Kreutzer RD, Barker DC, McCann SHE, Watts D, 1998. Geographic distribution and clinical description of leishmaniasis cases in Peru. Am J Trope Med Hyg 59 : 312–317. [Google Scholar]
  3. Guthmann JP, Arlt D, Garcia LM, Rosales M, de Jesus Sanchez J, Alvarez E, Lonlas S, Conte M, Bertoletti G, Fournier C, Huari R, Torreele E, Llanos-Cuentas A, 2005. Control of mucocutaneous leishmaniasis, a neglected disease: Results of a control programme in Satipo Province, Peru. Trop Med Int Health 10 : 856–862. [Google Scholar]
  4. Miranda-Verastegui C, Llanos-Cuentas A, Arevalo I, Ward BJ, Matlashewski G, 2005. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimonate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 40 : 1395–1403. [Google Scholar]
  5. Berman J, 2005. Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 14 : 1337–1346. [Google Scholar]
  6. Berman JD, 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24 : 684–703. [Google Scholar]
  7. Croft SL, 2001. Monitoring drug resistance in leishmaniasis. Trop Med Intern Health 6 : 899–905. [Google Scholar]
  8. Llanos-Cuentas A, Echevarria J, Cruz M, La Rosa A, Campos P, Campos M, Franke E, Berman J, Modabber F, Marr J, 1997. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of micosal leishmaniasis. Clin Infect Dis 25 : 677–684. [Google Scholar]
  9. Franke ED, Wignall FS, Cruz ME, Rosales E, Tovar AA, Lucas CM, Llanos-Cuentas A, Berman JD, 1990. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 113 : 934–940. [Google Scholar]
  10. Franke ED, Llanos-Cuentas A, Echevarria J, Cruz ME, Campos P, Tovar AA, Lucas CM, Berman JD, 1994. Efficacy of 2-day and 4-day regimens of sodium stibogluconate (pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 51 : 77–82. [Google Scholar]
  11. Marsden PD, Llanos-Cuentas EA, Lago EL, Cuba CC, Barreto AC, Costa JM, Jones TC, 1984. Human mucocutaneous leishmaniasis in tres bracos, Bahia-Brazil. An area of Leishmania braziliensis braziliensis transmission. III. Mucosal disease presentation and initial evolution. Rev Soc Bras Med Trop 17 : 179–186. [Google Scholar]
  12. Harbath S, Burke J, Lloyd J, Evans R, Pestotnik S, Samore M, 2002. Clinical and economical outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 35 : 120–127. [Google Scholar]
  13. Andersen EM, Cruz-Saldarriaga ME, Llanos-Cuentas A, Cjuno ML, Echevarria J, Miranda-Verastegui C, Colina O, Berman JD, 2005. Comparison of meglumine antimonate and pentamydine for Peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 72 : 133–137. [Google Scholar]
  14. Velez I, Agudelo S, Hendricks E, Puerta J, Grogl M, Modabber F, Berman J, 1997. Inefficacy of allopurinol for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann Intern Med 126 : 232–236. [Google Scholar]
  15. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF, 1992. Placebo-controlled clinical trial of sodium stibogluconate (pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 165 : 528–534. [Google Scholar]
  16. Mattock NM, Peters W, 1975. The experimental chemotherapy of leishmaniasis II. The activity in tissue culture of some antiparasitic and antimicrobial compounds in clinical use. Annals of Tropical Medicine and Parsitology 69 : 359–371. [Google Scholar]
  17. Teklemariam S, Hiwot AG, Frommel D, Miko TL, Ganlov G, Brycesson A, 1994. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 88 : 334–339. [Google Scholar]
  18. El-On J, Halevy S, Grunwald MH, Weinrauch L, 1992. Topical treatment of old world cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 27 : 227–231. [Google Scholar]
  19. Soto J, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, Berman JD, English CK, Grogl M, 2002. Treatment of cutaneous leishmaniasis with a topical anti leishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 66 : 147–151. [Google Scholar]
  20. Soto J, Hernandez N, Mejia H, Grogl M, Berman J, 1995. Successful treatment of new world cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin Infect Dis 20 : 47–51. [Google Scholar]
  21. Jha TK, Olliaro P, Thakur CPN, Kanyok TP, Singhania BL, Singh IJ, Singh NPK, Akhourny S, Jha S, 1998. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 316 : 1200–1205. [Google Scholar]
  22. Thakur CP, Kanvok TP, Pandey AK, Sinha GP, Messick C, Olliaro P, 2000. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 94 : 432–433. [Google Scholar]
  23. Romero GAS, Lessa HA, Orge MGO, Macedo VO, Marsden PD, 1998. Mucosal leishmaniasis treatment with aminosidine sulphate: results of two-year follow-up. Rev Soc Bras Med Trop 31 : 511–516. [Google Scholar]
  24. Lopez M, Inga R, Cangalaya M, Echevarría J, Llanos-Cuents A, Arevalo J, 1993. Diagnosis of Leishmania using the polymerase chain reaction: a simplified procedure for field work. Am J Trop Med Hyg 49 : 348–356. [Google Scholar]
  25. Soto J, Grogl M, Berman J, Olliaro P, 1994. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 88 : 695–698. [Google Scholar]
  26. Hepburn NC, Tidman MJ, Hunter JAA, 1994. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Top Med Hyg 88 : 700–703. [Google Scholar]
  27. Neal RA, Allen S, McCoy N, Olliaro P, Croft SL. 1995. The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 35 : 577–584. [Google Scholar]
  28. Croft SL, Sundar S, Fairlamb AH, 2006. Drug resistance in leishmaniasis. Clin Microbiol Rev 19 : 111–126. [Google Scholar]
  29. Thakur CP, Kanvok TP, Pandey AK, Sinha GP, Zaniewski AE, Houlihan HH, Olliaro P, 2000. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 94 : 429–431. [Google Scholar]
  30. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S, 2005. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect Dis 5 : 763–774. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.76.1128
Loading
/content/journals/10.4269/ajtmh.2007.76.1128
Loading

Data & Media loading...

  • Received : 23 Jan 2007
  • Accepted : 06 Feb 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error